Anbenitamab
Product Sizes
10 mg
£ POA
HY-P99437-10MG
5 mg
£ POA
HY-P99437-5MG
1 mg
£ POA
HY-P99437-1MG
About this Product
- SKU:
- HY-P99437
- Additional Names:
- KN-026
- CAS Number:
- 2367012-88-0
- Extra Details:
- Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer; HER2-positive metastatic breast cancer (MBC); gastric cancer; and gastroesophageal junction cancer[1][2][3][4].
- Molecular Weight:
- (145.16 kDa)
- Purity:
- 99.22
- References:
- [1]Dongmei Ji, et al. Abstract 3022: Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody. Cancer Res (2020) 80 (16_Supplement): 3022.|[2]Jian Zhang, et al. First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. Clin Cancer Res. 2022 Feb 15;28(4):618-628.|[3]Wang Z, et al. Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo. MAbs. 2024 Jan-Dec;16(1):2412881.|[4]Xu J, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur J Cancer. 2023 Jan;178:1-12.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
